Making the Cancer Journey Tolerable: Loprinzi Puts Focus on Symptoms
Charles L. Loprinzi, MD may have landed somewhat accidentally into the world of symptom management research, but once he arrived, he was there to stay.
BTK Inhibitors Mushroom in Blood Cancer Field
It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.
The Big Data Buzz
The power of that ability to analyze cancers over broad populations has generated much excitement in the drug development arena and it’s not hard to understand the reasons.
Robotic Surgery Represents a Notable Advance in Thyroid Cancer Care
Amid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.
Big Hopes for Big Data: Digital Information Focus Underpins Cancer Moonshot Goals
The ambitious goals of the Cancer Moonshot initiative, now incorporated into the recently enacted 21st Century Cures Act, are generating excitement among oncology leaders.
Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer
Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.
Challenges Persist in Deploying ADT in Prostate Cancer
In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.
When Values Collide: The Individual Versus the Common Good
It is perhaps a little unusual that an oncol­ogy commentary would begin with a highly provocative discussion about the future of driverless cars, but there are similarities in the sharp corners of the debate over this new tech­nology and emerging trends in cancer care.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.